Does methylphenidate cause growth suppression in children and adolescents?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Methylphenidate Suppress Growth and Development?

Yes, methylphenidate causes statistically significant but clinically modest growth suppression in children and adolescents, with reductions of approximately 2 cm in height and 2.7 kg in weight over 3 years of continuous treatment. However, this effect does not appear to compromise final adult height and requires regular monitoring rather than avoidance of treatment.

Magnitude of Growth Effects

The FDA label explicitly warns that CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients 1. Specifically, pediatric patients who received methylphenidate 7 days per week throughout the year experienced:

  • Approximately 2 cm less growth in height over 3 years
  • Approximately 2.7 kg less growth in weight over 3 years
  • No evidence of growth rebound during the 3-year development period studied 1

Recent research confirms these findings. A 2022 study showed z-scores for height decreased from baseline (0.002) to 24 months (-0.186), and weight z-scores decreased from 0.104 to -0.301 over the same period 2. A 2025 study similarly demonstrated significant reductions in both weight (P=0.001) and height (P=0.007) centiles over a mean treatment duration of 2.5 years 3.

Dose-Related Effects and Reversibility

The growth suppression is dose-dependent and appears to be reversible. The 2025 study found that weight centile reduction correlated with higher methylphenidate doses (P<0.0001), though this effect attenuated with longer treatment duration (P=0.005) 3. The 2022 guideline notes that effects are dose-related and similar for both methylphenidate and amphetamine 4.

Importantly, catch-up growth typically occurs during a 2-year period after methylphenidate withdrawal, and studies of final adult height show no statistically significant difference versus never-treated individuals 5.

Long-Term Safety Evidence

The largest long-term safety study (ADDUCE) followed 1,410 participants over 24 months and found little evidence of clinically significant growth effects after controlling for confounding variables. The 24-month height velocity SD score difference was -0.07 (95% CI -0.18 to 0.04; P=0.20), which was not statistically significant 6. This high-quality 2023 study provides reassurance that long-term methylphenidate treatment for 2 years is safe regarding growth.

Clinical Monitoring Requirements

The FDA mandates close monitoring of growth (weight and height) in all methylphenidate-treated pediatric patients 1. The 2019 AAP guidelines emphasize this requirement 7, and the 2025 study specifically recommends converting health data to percentiles for accurate monitoring and early identification of concerning trends 3.

Practical Monitoring Algorithm:

  • Measure height and weight at baseline before initiating treatment
  • Record measurements at least annually (though current practice shows only 42-44% adherence) 8
  • Plot measurements on growth charts using percentiles or z-scores
  • Consider treatment interruption if growth is significantly below expected trajectory 1

Mechanism and Special Considerations

The growth suppression is primarily attributed to reduced appetite, a highly frequent side effect of stimulant treatment 4. However, other possible mechanisms such as hormonal dysregulation require further investigation 4.

Height centile reduction may be more pronounced in taller children (P=0.008) 3, suggesting baseline growth characteristics should inform monitoring intensity.

Preschool-Aged Children

For children ages 4-5 years, the 2019 AAP guidelines express particular concern about "the lack of information and experience about longer-term effects on growth and brain development" in this population 7. The rate of metabolizing methylphenidate is slower in preschoolers, necessitating lower starting doses and smaller dose increments 7.

Clinical Decision-Making

The modest growth effects should not prevent methylphenidate use when clinically indicated. The benefits of treating ADHD—including improved quality of life, reduced functional impairment, and decreased risks of trauma, substance abuse, criminality, and unintentional injuries 4—typically outweigh the small, reversible effects on growth velocity.

Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted 1. This provides an opportunity for catch-up growth while reassessing the ongoing need for medication.

The 2022 guideline recommends that patients with ADHD should be periodically assessed, potentially including a medication-free interval, to determine whether there is continued need for treatment 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.